We'll be featuring our latest launches in FFPE proteomics, cell surface proteomics, and DynamiQ for oncology R&D.
Mapping pathway‑level mechanisms & molecular drivers behind signatures observed via high-content imaging.
Bridging the gap between genomic target discovery & functional target validation that provides proof of mechanism.
Enabling absolute quantitation of APOE4, BD-pTau217, Aβ42, GFAP, and NfL in a single multiplexed assay.
See how we decipher the heterogeneity in disease biology and patient response by integrating multiple layers of molecular data.
Uncovering meaningful physiological differences among patients who appear similar by diagnosis or lab values.
Novel biology is the key to discovery, and metabolomics enables scalable measure of varied functional metabolic states in humans.
On closing the gap between molecular measurement & clinical meaning, rapidly extracting actionable biological signals.
Discovering novel functional markers that capture tumor biology, TME interactions, and drug response/resistance in archived tissue.
Going beyond IHC to, for the first time, directly quantify the functional protein landscape of tumors in FFPE samples.
PharmaShots delves into Sapient’s mission to transform multi-omics research through innovation & world-class partnerships.
Extending molecular insights beyond DNA and RNA to realize new value in existing FFPE tissue biobanks.
